Deadline for manuscript submissions: closed (31 March 2010)
Special Issue Editor
Guest Editor Dr. Sonia Pearson-White
Scientific Program Manager, The Biomarkers Consortium Foundation for the National Institutes of Health, F9650 Rockville Pike, Bethesda, MD 20814, USA
E-Mail: firstname.lastname@example.org Phone: +1 301-435-4103 Interests: molecular genetics; biomarkers; oncology; TGF-beta signaling oncogene/proto-oncogene; stem cells
Special Issue Information
The 2004 FDA Critical Path Initiative challenged the pharmaceutical industry to reduce the time (12-15 years) and expense (~$1-2 billion) to bring an oncology drug to market. Biomarkers are seen as key to reducing the time and expense for this. There are thousands of cancer-related biomarker references in the literature, but only a handful of oncology biomarkers have been validated for clinical use. We are interested in papers covering all aspects of biomarker discovery, validation, and qualification in any area of oncology (see cancer list at http://www.mdpi.com/journal/cancers/about). Biomarkers can be circulating molecules or cells, pharmacogenomics, GWAS, or imaging. Biomarker measurements can include techniques such as microarray analyses or signature combinations from microarrays (e.g. Mammaprint(tm)), new assays for measuring known biomarkers such as HER2 or ER, reverse phase protein microarray (RPMA), circulating tumor cells, and imaging science studies (e.g. FDG-PET, DCE-MRI, DW-MRI, MR spectroscopy). Of particular interest are biomarkers based on fundamental understanding of cancer biology, or that add to that understanding.